非糖尿病患者心衰风险降低27% AZ公布达格列净详细3期结果(2)
2019-11-15 未知 admin
[2] Farxiga’s DAPA-HF trial at ESC. Retrieved September 1, 2019, from https://www.astrazeneca.com/content/dam/az/PDF/2019/AZN%20ESC%20DAPA-HF%202019.pdf
▽关注【药明康德】微信公众号
鐑瘝锛